Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Childs

Dermatology College Station, TX Medical Doctor

NPI 1023150083 CMS profile 227261

1605 Rock Prairie Rd, Ste 312, College Station, TX 77845

Open in the dashboard

General payments

$19,646

1,181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Childs of College Station, TX is reported in the CMS Open Payments database as having received $19,646 across 1,181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,183 161
2024 General $3,320 182
2023 General $3,950 220
2022 General $3,101 212
2021 General $2,361 143
2020 General $1,607 114
2019 General $2,125 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Childs
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to James Childs were reported at $3,183. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year James Childs Dermatology median Middle half National median
2019 $2,125 $454 $129–$1,240 $163
2020 $1,607 $235 $81–$756 $114
2021 $2,361 $377 $108–$1,108 $132
2022 $3,101 $514 $143–$1,391 $149
2023 $3,950 $607 $159–$1,674 $160
2024 $3,320 $751 $204–$1,903 $164
2025 $3,183 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $2,591 98 payments
  2. Mayne Pharma Inc. $2,123 259 payments
  3. Amgen Inc. $1,270 48 payments
  4. Novartis Pharmaceuticals Corporation $1,194 145 payments
  5. Incyte Corporation $1,072 42 payments
  6. AbbVie, Inc. $973 57 payments
  7. Lilly USA, LLC $973 44 payments
  8. Galderma Laboratories, L.P. $925 56 payments
  9. Almirall LLC $901 49 payments
  10. Medimetriks Pharmaceuticals, Inc. $860 17 payments
  11. Other $6,764 366 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,725 1,173 payments
  2. Consulting Fee $700 2 payments
  3. Education $221 6 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $2,177 77 payments
  2. Otezla $1,238 46 payments
  3. OPZELURA $1,065 41 payments
  4. STELARA $942 42 payments
  5. TALTZ $831 42 payments
  6. SIMPONI ARIA $831 36 payments
  7. SIMPONI $831 36 payments
  8. SKYRIZI $769 46 payments
  9. VTAMA $759 30 payments
  10. Winlevi $644 30 payments
  11. Other $14,445 911 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

87

Median for Dermatology: 534

Drug cost

$11,360

Median for Dermatology: $67,151

Branded share of claims

13.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eucrisa Crisaborole Brand 12 $8,901
Clobetasol Propionate Generic 23 $947
Doxycycline Hyclate Generic 13 $685
Desonide Generic 11 $411
Imiquimod Generic 12 $312
Mupirocin Generic 16 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
$488 — —
TREMFYA
$359 — —
Otezla
$285 — —
VTAMA
$245 — —
Seysara
$235 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record